Clinical trials: ASCVD
Hyperlipidemias
A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy
The purpose of this study is to determine if Bempedoic Acid (BA) + Ezetimibe (EZE) in a fixed-dose combination (FDC) is effective and safe versus its individual components and placebo in patients with elevated LDL cholesterol…
- Trial name
- NCT03337308
- Testing
- Bempedoic Acid + Ezetimibe Fixed-Dose Combination, Bempedoic Acid, Ezetimibe
- Where
- 5 sites in United States
- Volunteers
- 382 people
- Sponsor
- Esperion Therapeutics, Inc.
Atherosclerosis, Cardiovascular Disease
A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease
The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.
- Conditions
- Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
- Trial name
- HEART-3 (NCT07839936)
- Testing
- VERVE-102
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Verve Therapeutics, Inc.
Type 2 Diabetes Mellitus, Arteriosclerotic Cardiovascular Disease
Observational Study of ASCVD Risks of Type 2 Diabetes in East China
The aim of this study is to screen patients with type 2 diabetes with high risk of cardiovascular disease, and intervene with or without Glucagon like peptide-1 receptor agonists.
- Conditions
- Type 2 Diabetes Mellitus, Arteriosclerotic Cardiovascular Disease, Liraglutide
- Trial name
- NCT04866667
- Where
- China
- Volunteers
- 316 people
- Sponsor
- Zhejiang Provincial People's Hospital
Atherosclerotic Cardiovascular Disease
The Belgian REAL (BE.REAL) Registry
This is an observational non-interventional study. The visit schedule is according to the routine clinical practice. Only data corresponding to study variables within the specified study period will be collected.
- Trial name
- BE REAL (NCT05726838)
- Testing
- Inclisiran
- Volunteers
- 600 people
- Sponsor
- Novartis Pharmaceuticals
Primary Hypercholesterolemia, Mixed Dyslipidemia
A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
This study is to generate post-marketing safety and effectiveness data of inclisiran sodium in Indian patients as per approved indication i.e., primary hypercholesterolemia (heterozygous familial and non-familial) or mixed…
- Trial name
- NCT06386419
- Testing
- inclisiran
- Where
- 9 sites in India
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)
The purpose of this study is to characterize the distribution of lipoprotein(a) (Lp(a)) levels among participants with a history of ASCVD as defined by their medical history and is 2-fold: Evaluate the distribution of Lp(a) value…
- Trial name
- NCT05378529
- Testing
- Lp(a) Screening
- Where
- 735 sites in United States, Argentina and 34 more
- Volunteers
- 39,480 people
- Sponsor
- Amgen
Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.
- Trial name
- MOVE-Lp(a) (NCT07157774)
- Testing
- Muvalaplin
- Where
- 804 sites in United States, Argentina and 26 more
- Volunteers
- 10,450 people
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World
This is a retrospective database study which includes administrative medical and pharmacy claims linked with clinical and laboratory measurements for patients in the US, to evaluate the effectiveness of once-weekly semaglutide…
- Conditions
- Overweight, Obesity, Atherosclerotic Cardiovascular Disease (ASCVD)
- Trial name
- SCORE (NCT06874751)
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 45,456 people
- Sponsor
- Novo Nordisk A/S
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
A Multinational Survey-based Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Cardiologists
The purpose of this survey is to collect information for scientific research and to better understand the role of systemic inflammation in identification, treatment and management of patients with ASCVD and CKD.
- Trial name
- FLAME-ASCVD (NCT05755373)
- Testing
- No treatment given
- Where
- India
- Volunteers
- 602 people
- Sponsor
- Novo Nordisk A/S
ASCVD, LDL-C
Test 2 Treat: Can we Improve the Testing and Treatment of High Cholesterol in Patients Who Have Been Hospitalized for a Cardiac Event by Providing Education to Doctors and Patients?
The goal of this implementation trial is to learn if providing education to doctors and patients who have had a heart event works to prevent future heart problems. The main questions it aims to answer are: 1.
- Trial name
- T2T (NCT06471036)
- Testing
- Care Champion Intervention
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Duke University
ASCVD, ASCVD Management
Coronary Artery Calcium (CAC) Testing in Primary Care
The goal of this study is to improve how primary care providers identify and manage patients at risk for heart disease. One tool that can help with this is a coronary artery calcium (CAC) test, which looks for calcium buildup in…
- Conditions
- ASCVD, ASCVD Management, Coronary Artery Calcium, Hyperlipidemia
- Trial name
- NCT07868809
- Testing
- Our Practice Advisory (OPA)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Weill Medical College of Cornell University
Dyslipidemia, Subclinical hypothyroïdism
Thyroid Hormone Replacement for Subclinical Hypothyroidism and Dyslipidemia in ASCVD (ThyroHeart-Lipid Study)
In ASCVD patients complicated with subclinical hypothyroidism, the percentage of those who did not reach the target of lipid-lowering therapy (LDL-C>1.8mmol/L) is usually higher than that in population with normal thyroid…
- Conditions
- Dyslipidemia, Subclinical hypothyroïdism, Statin, ASCVD
- Trial name
- NCT03606824
- Testing
- Pitavastatin and levothyroxine
- Where
- China
- Volunteers
- 248 people
- Sponsor
- Shaochun.Li
Type 2 Diabetes, Overweight
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Conditions
- Type 2 Diabetes, Overweight, ASCVD
- Trial name
- INTERCEPT (NCT07417618)
- Testing
- Dulaglutide, Semaglutide, Tirzepatide
- Where
- United States
- Volunteers
- 60,000 people
- Sponsor
- Brigham and Women's Hospital
Atherothrombotic Diseases, Atherosclerotic Cardiovascular Disease (ASCVD)
Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease
The EPOCA study (Evaluation of a POlypill and Colchicine for risk reduction in patients with established Atherosclerotic cardiovascular disease) will be a randomized, superiority, parallel, 2x2 factorial, multicenter clinical…
- Trial name
- EPOCA (NCT06930885)
- Testing
- Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin), Colchicine 0.5 mg, Usual Care Group
- Where
- 13 sites in Brazil
- Volunteers
- 7,713 people
- Sponsor
- Hospital do Coracao
Pre Diabetes, ASCVD
Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus (PROVE-DM)
This study is to evaluating the impact of low-intensity statin plus ezetimibe versus high-intensity statin therapy on risk of new-onset diabetes mellitus in patients with atherosclerotic cardiovascular disease who have…
- Trial name
- NCT05579626
- Testing
- high-intensity statin arm, low-intensity statin plus ezetimibe
- Where
- 31 sites in South Korea
- Volunteers
- 4,000 people
- Sponsor
- Seung-Whan Lee, M.D., Ph.D.
Cardiovascular Diseases, Atherosclerosis
Maternal and Offspring Outcomes in Pregnant Women With Pre-existing ASCVD
A growing body of evidence supports associations between cardiovascular health and adverse pregnancy outcome and between adverse pregnancy outcome and atherosclerotic cardiovascular disease and builds on the well-established…
- Conditions
- Cardiovascular Diseases, Atherosclerosis, Pregnancy Complications, Adverse Cardiac Event
- Trial name
- CVD_OBS (NCT06406998)
- Testing
- Pre-existing atherosclerotic cardiovascular disease
- Where
- South Korea
- Volunteers
- 5,461,222 people
- Sponsor
- Samsung Medical Center
Atherosclerosis, Cardiovascular Disease
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
The purpose of this study is to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazakizumab compared with placebo in adults who have elevated hsCRP and at increased…
- Conditions
- Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension
- Trial name
- CLARITY-CRP (NCT07783802)
- Testing
- Clazakizumab
- Where
- 46 sites in United States, Argentina and 2 more
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Coronary Heart Disease (CHD)
VICTORION-ASCERTAIN: Implementation Study (v-ASCERTAIN)
The goal of this study is to understand and compare an alternative model of care in comparison to the usual model of care in include male and female participants ≥18 years of age with a history of ASCVD (hear and blood vessels…
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Coronary Heart Disease (CHD), Cerebrovascular Disease, Peripheral Arterial Disease (PAD)
- Trial name
- v-ASCERTAIN (NCT05834673)
- Testing
- SMS messages, Telephone-based support calls, GP Education
- Where
- Australia
- Volunteers
- 6 people
- Sponsor
- Monash University
Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk, Elevated Cholesterol
A Research Study Looking at the Effect of Food Intake on How the Medicine NN0385-0434 Behaves in the Body of Healthy Participants
In this study participants will receive NNC0385-0434. NNC0385-0434 is being developed for the treatment of hypercholesterolemia, a fat metabolism disorder characterized by high levels of cholesterol in the blood.
- Conditions
- Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk, Elevated Cholesterol, Healthy Volunteers
- Trial name
- NCT05091073
- Testing
- NNC0385-0434
- Where
- Germany
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Systemic Inflammatory Response Syndrome
Serum Level of Lipopolysaccharide-binding Protein (LBP) and Atherosclerosis in Hemodialysis Patients
Background In hemodialysis (HD) patients, impaired gut barrier and alteration in microbiota in the gut is thought to increase the risk of bacterial translocation and chronic inflammation.
- Trial name
- NCT03427307
- Where
- Taiwan
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Tungs' Taichung Metroharbour Hospital